Homayoun Amini

Homayoun Amini

Auto-generated profile, based on publicly available information

Homayoun Amini

Department of Psychiatry, Roozbeh Hospital, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2005 in Phytotherapy Research
Verified
Journal Article
Closed access
PDF file
SAShahin Akhondzadeh
Shahin Akhondzadeh
NTNajaf Tahmacebi‐Pour
Najaf Tahmacebi‐Pour
ANAhamad‐Ali Noorbala
Ahamad‐Ali Noorbala
HAHomayoun Amini
Homayoun Amini
HFHassan Fallah‐Pour
Hassan Fallah‐Pour
MKMousa Khani
Mousa Khani

1 January 2008 in Australian & New Zealand Journal of Psychiatry
Verified
Journal Article
Closed access
SJShima Jazayeri
Shima Jazayeri
MTMehdi Tehrani-Doost
Mehdi Tehrani-Doost
SKSeyed A. Keshavarz
Seyed A. Keshavarz
MHMostafa Hosseini
Mostafa Hosseini
ADAbolghassem Djazayery
Abolghassem Djazayery
MPMalcolm Peet
Malcolm Peet
Objective: To compare therapeutic effects of eicosapentaenoic acid (EPA), fluoxetine and a combination of them in major depression. Method: Sixty outpatients with a diagnosis of major depressive disorder based on DSM-IV criteria and a score ≥15 in the 17-item Hamilton Depression Rating Scale (HDRS) were randomly allocated to receive daily either 1000 mg EPA or 20 mg fluoxetine, or their combination for 8 weeks. Double dummy technique was used to double blind the study. Patients were assessed at 2 week intervals. Change in HDRS was the primary outcome measure. Results: Analysis of covariance for HDRS at week 8 across treatment groups was performed in 48 patients who completed at least 4 weeks of the study, with the last observation carried forward. Treatment, age of onset and baseline HDRS had a significant effect on HDRS at week 8. EPA + fluoxetine combination was significantly better than fluoxetine or EPA alone from the fourth week of treatment. Fluoxetine and EPA appear to be equally effective in controlling depressive symptoms. Response rates (≥50% decrease in baseline HDRS) were 50%, 56% and 81% in the fluoxetine, EPA and combination groups, respectively. Conclusions: In the present 8 week trial EPA and fluoxetine had equal therapeutic effects in major depressive disorder. EPA + fluoxetine combination was superior to either of them alone.

1 January 2005 in Clinical Practice & Epidemiology in Mental Health
Verified
Journal Article
Open access
MMMohammad-Reza Mohammadi
Mohammad-Reza Mohammadi
HDHaratoon Davidian
Haratoon Davidian
ANAhmad Noorbala
Ahmad Noorbala
HMHossein Malekafzali
Hossein Malekafzali
HNHamid Naghavi
Hamid Naghavi
AGAhmad Ghanizadeh
Ahmad Ghanizadeh
The nation-wide epidemiological survey of psychiatric disorders in term of lifetime prevalence is not adequately known in Iran. The prevalence of lifetime psychiatric disorders was estimated among the population of aged 18 and over on gender, age group, educational level, occupational status, marital status, and residential area. The subjects were 25,180 individuals selected through a clustered random sampling method. The psychiatric disorders were diagnosed on the bases of Diagnostic and Statistical Manual of Mental Disorders-IV criteria. It is the first study in which the structured psychiatric interview administered to a representative sample of the Iranian population age 18 and over by the 250 trained clinical psychologist interviewers. The data was entered through EPI-Info software twice in an attempt to prevent any errors and SPSS-11 statistical software was also used for analyses. The odds ratios and their confidence intervals estimated by using logistic regression. The prevalence of psychiatric disorders was 10.81%. It was more common among females than males (14.34% vs. 7.34%, P < 0.001). The prevalence of anxiety and mood disorders were 8.35% and 4.29% respectively. The prevalence of psychotic disorders was 0.89%; neuro-cognitive disorders, 2.78% and dissociative disorders, 0.77%. Among mood disorders, major depressive disorder (2.98%) and among anxiety disorders, phobic disorder (2.05%) had the higher prevalence. The prevalence of psychiatric disorders among divorced and separated 22.31%; residents of urban areas 11.77%; illiterates 13.80%; householders 15.48%; unemployed 12.33% that were more than other groups. The mental health pattern in Iran is similar to the western countries, but it seems that the prevalence of psychiatric disorders in Iran may be lower than these countries. It is estimated that at least about 7 millions of Iranian population suffer from one or more of the psychiatric disorders. It shows the importance of the role of the psychiatric disorders in providing preventive and management programs in Iran.

1 September 2003 in Progress in Neuro-Psychopharmacology and Biological Psychiatry
Verified
Journal Article
Closed access
SAShahin Akhondzadeh
Shahin Akhondzadeh
ANAli Akbar Nejatisafa
Ali Akbar Nejatisafa
HAHomayoun Amini
Homayoun Amini
MMMohammad Reza Mohammadi
Mohammad Reza Mohammadi
BLBagher Larijani
Bagher Larijani
AKAbbas Kamalipour
Abbas Kamalipour

1 June 2010 in Psychiatry Research
Verified
Journal Article
Closed access
SJShima Jazayeri
Shima Jazayeri
SKSeyed A. Keshavarz
Seyed A. Keshavarz
MTMehdi Tehrani-Doost
Mehdi Tehrani-Doost
MDMahmood Djalali
Mahmood Djalali
MHMostafa Hosseini
Mostafa Hosseini
ADAbolghassem Djazayery
Abolghassem Djazayery

1 January 2009 in Comprehensive Psychiatry
Verified
Journal Article
Closed access
VSVandad Sharifi
Vandad Sharifi
SASeyed Mohammad Assadi
Seyed Mohammad Assadi
MMMohammad Reza Mohammadi
Mohammad Reza Mohammadi
HAHomayoun Amini
Homayoun Amini
HKHossein Kaviani
Hossein Kaviani
MJMohsen Jalali
Mohsen Jalali